Last reviewed · How we verify

Feminizing hormone therapy

Asociación Civil Impacta Salud y Educación, Peru · FDA-approved active Small molecule Quality 5/100

Feminizing hormone therapy is a Small molecule drug developed by Asociación Civil Impacta Salud y Educación, Peru. It is currently FDA-approved.

At a glance

Generic nameFeminizing hormone therapy
SponsorAsociación Civil Impacta Salud y Educación, Peru
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Feminizing hormone therapy

What is Feminizing hormone therapy?

Feminizing hormone therapy is a Small molecule drug developed by Asociación Civil Impacta Salud y Educación, Peru.

Who makes Feminizing hormone therapy?

Feminizing hormone therapy is developed and marketed by Asociación Civil Impacta Salud y Educación, Peru (see full Asociación Civil Impacta Salud y Educación, Peru pipeline at /company/asociaci-n-civil-impacta-salud-y-educaci-n-peru).

What development phase is Feminizing hormone therapy in?

Feminizing hormone therapy is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing